The New York Times reports that Emory University psychiatrist Charles B. Nemeroff failed to report $1.2 million he earned from consulting with pharmaceutical companies. If true, this would violate federal research rules. According to the article:
In one telling example, Dr. Nemeroff signed a letter dated July 15, 2004, promising Emory administrators that he would earn less than $10,000 a year from GlaxoSmithKline to comply with federal rules. But on that day, he was at the Four Seasons Resort in Jackson Hole, Wyo., earning $3,000 of what would become $170,000 in income that year from that company — 17 times the figure he had agreed on.
Dr Nemeroff “has written more than 850 research reports and reviews. He was editor in chief of the influential journal Neuropsychopharmacology,” according to the Times.
This is just the latest in several recent embarrassing moments for psychiatry involving the profession’s financial ties with pharmaceutical companies. As reported earlier on AHP, nearly 1/3 of the American Psychiatric Association’s budget comes directly from the pharmaceutical industry (here), and the New York Times has called on the US Congress to pass legislation that will force pharmaceutical companies to publicly disclose all payments they make to physicians (here). The Times reports that this “series of disclosures that is shaking the world of academic medicine and seems likely to force broad changes in the relationships between doctors and drug makers.”